Swedish Orphan Biovitrum AB (publ) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Swedish Orphan Biovitrum AB (publ) stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOVF, but not buy additional shares or sell existing shares.
View analyst ratings for Swedish Orphan Biovitrum AB (publ) or view top-rated stocks.

Wall Street analysts have given Swedish Orphan Biovitrum AB (publ) a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Swedish Orphan Biovitrum AB (publ) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Swedish Orphan Biovitrum AB (publ) is scheduled to release its next quarterly earnings announcement on Thursday, July 15th 2021.
View our earnings forecast for Swedish Orphan Biovitrum AB (publ).

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) announced its quarterly earnings data on Tuesday, May, 4th. The company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $0.03. The company had revenue of $436.23 million for the quarter, compared to analysts' expectations of $450 million. Swedish Orphan Biovitrum AB (publ) had a net margin of 19.63% and a trailing twelve-month return on equity of 12.50%.
View Swedish Orphan Biovitrum AB (publ)'s earnings history.

Swedish Orphan Biovitrum AB (publ)'s stock was trading at $20.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOVF shares have decreased by 6.3% and is now trading at $18.75.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Swedish Orphan Biovitrum AB (publ) include Sysmex (SSMXY), 10x Genomics (TXG), Exact Sciences (EXAS), Fresenius Medical Care AG & Co. KGaA (FME), Horizon Therapeutics Public (HZNP), Sino Biopharmaceutical (SBMFF), Bitcoin Group (BTGGF), Avantor (AVTR), Alnylam Pharmaceuticals (ALNY), Eurofins Scientific (ERFSF), MERCK Kommanditgesellschaft auf Aktien (MRK), Smith & Nephew (SNN), The Cooper Companies (COO), Insulet (PODD) and Teleflex (TFX).
View all of BIOVF's competitors.

Swedish Orphan Biovitrum AB (publ) trades on the OTCMKTS under the ticker symbol "BIOVF."

Shares of BIOVF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOVF stock can currently be purchased for approximately $18.75.

Swedish Orphan Biovitrum AB (publ) has a market capitalization of $5.62 billion and generates $1.66 billion in revenue each year. The company earns $353.70 million in net income (profit) each year or $1.04 on an earnings per share basis.

Swedish Orphan Biovitrum AB (publ) employs 1,509 workers across the globe.

The official website for Swedish Orphan Biovitrum AB (publ) is www.sobi.com.

Swedish Orphan Biovitrum AB (publ) is headquartered at Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76.

Swedish Orphan Biovitrum AB (publ)'s mailing address is Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76. The company can be reached via phone at 46-8697-2000 or via email at [email protected]